These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9797791)

  • 1. Pharmacokinetic interaction between ritonavir and clarithromycin.
    Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
    Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
    Boruchoff SE; Sturgill MG; Grasing KW; Seibold JR; McCrea J; Winchell GA; Kusma SE; Deutsch PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):351-9. PubMed ID: 10801243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
    Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
    Sekar VJ; Spinosa-Guzman S; De Paepe E; De Pauw M; Vangeneugden T; Lefebvre E; Hoetelmans RM
    J Clin Pharmacol; 2008 Jan; 48(1):60-5. PubMed ID: 18094220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
    Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
    Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
    Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
    Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
    Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
    Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir.
    Cato A; Cao G; Hsu A; Cavanaugh J; Leonard J; Granneman R
    Drug Metab Dispos; 1997 Sep; 25(9):1104-6. PubMed ID: 9311629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
    Winston A; Back D; Fletcher C; Robinson L; Unsworth J; Tolowinska I; Schutz M; Pozniak AL; Gazzard B; Boffito M
    AIDS; 2006 Jun; 20(10):1401-6. PubMed ID: 16791014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.
    McCance-Katz EF; Moody DE; Smith PF; Morse GD; Friedland G; Pade P; Baker J; Alvanzo A; Jatlow P; Rainey PM
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S235-46. PubMed ID: 17109310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of drug interaction between rifampicin and clarithromycin which are used for treating pulmonary Mycobacterium avium complex infection].
    Taki H; Ogawa K; Nakagawa T; Kashima K; Tarumi O; Saitou Y; Yamada N; Tano M; Nikai T
    Kekkaku; 2007 Aug; 82(8):641-6. PubMed ID: 17874572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
    Glesby MJ; Aberg JA; Kendall MA; Fichtenbaum CJ; Hafner R; Hall S; Grosskopf N; Zolopa AR; Gerber JG;
    Clin Pharmacol Ther; 2005 Aug; 78(2):143-53. PubMed ID: 16084849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.